Gracell Biotechnologies receives shareholder approval for merger with AstraZeneca

seekingalpha02-20

Gracell Biotechnologies (NASDAQ:GRCL) said on Tuesday that its shareholders have approved a proposed merger between the China-based biopharmaceutical company and AstraZeneca (AZN). The extraordinary ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2412174970?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359851661/image_1359851661.jpg","is_english":true,"pubTime":"2024-02-20 21:09","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2412174970","market":"us","top_or_hot":-1,"title":"Gracell Biotechnologies receives shareholder approval for merger with AstraZeneca","media":"seekingalpha","content":"<div>\n<p>Gracell Biotechnologies (NASDAQ:GRCL) said on Tuesday that its shareholders have approved a proposed merger between the China-based biopharmaceutical company and AstraZeneca (AZN). The extraordinary ...</p>\n\n<a href=\"https://seekingalpha.com/news/4068799-gracell-biotechnologies-receives-shareholder-approval-for-merger-with-astrazeneca\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gracell Biotechnologies receives shareholder approval for merger with AstraZeneca</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGracell Biotechnologies receives shareholder approval for merger with AstraZeneca\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-20 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4068799-gracell-biotechnologies-receives-shareholder-approval-for-merger-with-astrazeneca><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gracell Biotechnologies (NASDAQ:GRCL) said on Tuesday that its shareholders have approved a proposed merger between the China-based biopharmaceutical company and AstraZeneca (AZN). The extraordinary ...</p>\n\n<a href=\"https://seekingalpha.com/news/4068799-gracell-biotechnologies-receives-shareholder-approval-for-merger-with-astrazeneca\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://seekingalpha.com/news/4068799-gracell-biotechnologies-receives-shareholder-approval-for-merger-with-astrazeneca","article_id":"2412174970","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359851661/image_1359851661.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2412174970","pubTimestamp":1708434593,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Gracell Biotechnologies  said on Tuesday that its shareholders have approved a proposed merger between the China-based biopharmaceutical company and AstraZeneca . The extraordinary general meeting of the shareholders was held on Feb. 19. At least 458.3M of the company's total outstanding ordinary shares, par value of $0.0001 per share, including ordinary shares represented by the company's American Depositary Shares, attended the EGM in person or by proxy. The shares represented ~94.8% of the total outstanding votes on the record date of Jan. 8.  The proposed merger was approved by ~99.9% of the total votes cast at the EGM. The merger is expected to close on or around Feb. 22. Source: Press Release    More on Gracell Biotechnologies  With Its Sale To AstraZeneca, Gracell Blazes Exit Trail For Cash-Challenged Chinese Biotechs Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win AstraZeneca to buy Gracell Biotechnologies for $1.2 billion Gracell gains as FDA clears another ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","AZN":"阿斯利康","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4535":"淡马锡持仓","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念","GRCL":"亘喜生物","BK4139":"生物科技","BK4007":"制药"},"translate_title":"格雷斯生物技术公司获得股东批准与阿斯利康合并","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1,"GRCL":1},"content_text":"Gracell Biotechnologies (NASDAQ:GRCL) said on Tuesday that its shareholders have approved a proposed merger between the China-based biopharmaceutical company and AstraZeneca (AZN). The extraordinary general meeting of the shareholders was held on Feb. 19. At least 458.3M of the company's total outstanding ordinary shares, par value of $0.0001 per share, including ordinary shares represented by the company's American Depositary Shares, attended the EGM in person or by proxy. The shares represented ~94.8% of the total outstanding votes on the record date of Jan. 8.  The proposed merger was approved by ~99.9% of the total votes cast at the EGM. The merger is expected to close on or around Feb. 22. Source: Press Release    More on Gracell Biotechnologies  With Its Sale To AstraZeneca, Gracell Blazes Exit Trail For Cash-Challenged Chinese Biotechs Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win AstraZeneca to buy Gracell Biotechnologies for $1.2 billion Gracell gains as FDA clears another study for lead asset Seeking Alpha’s Quant Rating on Gracell Biotechnologies","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2412174970"}